Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 35OTHER 29INDUSTRY 6OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 3Zoledronic Acid 3Saline Solution 3Gemcitabine 3enzalutamide 2darolutamide 2Radiosurgery 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 2Androgen Antagonists 2Abiraterone Acetate 2veliparib 1toripalimab 1bemarituzumab 1avelumab 1apatorsen 1apalutamide 1anlotinib 1aldesleukin 1abiraterone 1Watchful Waiting 1Videotape Recording 1Urination 1Ultrasound, High-Intensity Focused, Transrectal 1Transurethral Resection of Prostate 1Tacrolimus 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × aldesleukin × Genitourinary × Clear all
NCT04383067 2021-02-11

A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

Sheba Medical Center

Phase 2 Unknown
20 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡